Onycholysis with the appearance of a "sunset" secondary to capecitabine

Cutis

Volumn 72, Issue 3, 2003, Pages 234-236

  Maino, Kimberly L ^a   Norwood, Christopher ^a   Stashower, Mitchell E ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE;

ADULT; ANAMNESIS; ARTICLE; BREAST CARCINOMA; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; HUMAN; ONYCHOLYSIS; PHYSICAL EXAMINATION;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; ERYTHEMA; FEMALE; HUMANS; HYPERPIGMENTATION; NAIL DISEASES;

EID: 0141889963     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Susser W, Whitaker-Worth D, Grant-Kels J. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367-398.
2. Chen G, Chen Y, Hsu M, et al. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol. 2001;145:521-522.
3. Reigner B. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40:85-104.
4. Dooley M. Capecitabine. Drugs. 1999;58:69-76.
5. Bell K, Perna A, Hsu S. Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer [letter]. J Am Acad Dermatol. 2001;45:790-791.
6. Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology. 1999;57(suppl 1):27-32.
7. Hussain S, Anderson DN, Salvatti ME, et al. Onycholysis as a complication of systemic chemotherapy. Cancer. 2000;88:2367-2371.